V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.